<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40910183</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>05</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1753-0407</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>9</Issue><PubDate><Year>2025</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of diabetes</Title><ISOAbbreviation>J Diabetes</ISOAbbreviation></Journal><ArticleTitle>Indobufen Versus Aspirin Plus Clopidogrel in Patients After Coronary Stenting in Patients With Diabetes: A Post Hoc Analysis of the OPTION Trial.</ArticleTitle><Pagination><StartPage>e70152</StartPage><MedlinePgn>e70152</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e70152</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1111/1753-0407.70152</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Despite increased risk of ischemic events in diabetes, the optimal anti-thrombotic strategy for secondary prevention has not been defined. We aimed to assess the efficacy and safety of optimal antiplatelet agents such as indobufen-based dual antiplatelet therapy (DAPT) in patients with diabetes after coronary stenting.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">OPTION trial was a randomized, open-label, noninferiority, and multicentric study in China. Enrolled subjects were randomized 1:1 to indobufen-based DAPT or aspirin-based DAPT. This post hoc analysis from OPTION trial was performed by the presence of diabetes. The primary endpoint was a 1-year composite of cardiovascular death, nonfatal myocardial infarction, ischemic stroke, definite or probable stent thrombosis, or Bleeding Academic Research Consortium (BARC) criteria type 2, 3, or 5 bleeding.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 4551 OPTION patients, the primary endpoint occurred in 93/1570 patients with diabetes (5.92%), as compared to 148/2981 without diabetes (4.96%) (HR: 0.72, 95% CI: 0.47-1.08, and HR: 0.73, 95% CI: 0.53-1.01, respectively), without significant interaction between diabetes status and treatment effect (P<sub>interaction</sub>&#x2009;=&#x2009;0.935). The secondary efficacy endpoint was comparable between patients with (HR: 1.31, 95% CI: 0.60-2.84) and without diabetes (HR: 0.95, 95% CI: 0.51-1.76) (P<sub>interaction</sub>&#x2009;=&#x2009;0.526). Similarly, both subgroups derived similar benefits for the safety endpoint (HR, 0.56; 95% CI, 0.34-0.92 for subjects with diabetes vs. HR, 0.66; 95% CI, 0.45-0.98 for those without diabetes; P<sub>interaction</sub>&#x2009;=&#x2009;0.609).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In patients receiving DES implantation, indobufen-based DAPT might be considered as a reasonable alternative to aspirin-based DAPT in the secondary prevention for those with diabetes, especially in patients at high bleeding risk.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). Journal of Diabetes published by Ruijin Hospital, Shanghai JiaoTong University School of Medicine and John Wiley &amp; Sons Australia, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Shujing</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, National Clinical Research Center for Interventional Medicine, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Huajie</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, National Clinical Research Center for Interventional Medicine, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Disease, Zhongshan Hospital, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Lili</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, National Clinical Research Center for Interventional Medicine, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, Shanghai Geriatric Medical Center, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Huanyi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Taian City Central Hospital, Taian, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Kang</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Xi'an no. 3 Hospital, the Affiliated Hospital of Northwest University, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xiaoyan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Affiliated Hospital of Jiangnan University, Wuxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Manhua</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiology, The Central Hospital of Wuhan, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Guangping</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Cardiology, The Second Hospital of Tianjin Medical University, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Jiangnan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lan</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Dongguan Third People's Hospital, Dongguan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Guanghe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Affiliated Hospital of Jining Medical University, Jining, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, National Clinical Research Center for Interventional Medicine, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qi</LastName><ForeName>Zhiyong</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, National Clinical Research Center for Interventional Medicine, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qian</LastName><ForeName>Juying</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, National Clinical Research Center for Interventional Medicine, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Hongyi</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-4773-1962</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, National Clinical Research Center for Interventional Medicine, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ge</LastName><ForeName>Junbo</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, National Clinical Research Center for Interventional Medicine, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>OPTION investigators</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NA</GrantID><Agency>Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd</Agency><Country/></Grant><Grant><GrantID>19MC1910300</GrantID><Agency>Shanghai Clinical Research Center for Interventional Medicine</Agency><Country/></Grant><Grant><GrantID>2020ZSLC57</GrantID><Agency>Clinical Research Special Fund of Zhongshan Hospital Fudan University</Agency><Country/></Grant><Grant><GrantID>81970298</GrantID><Agency>National Natural Science Foundation of China General Program</Agency><Country/></Grant><Grant><GrantID>20214Y0139</GrantID><Agency>Research Project of Shanghai Municipal Health Commission</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>J Diabetes</MedlineTA><NlmUniqueID>101504326</NlmUniqueID><ISSNLinking>1753-0407</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>R16CO5Y76E</RegistryNumber><NameOfSubstance UI="D001241">Aspirin</NameOfSubstance></Chemical><Chemical><RegistryNumber>A74586SNO7</RegistryNumber><NameOfSubstance UI="D000077144">Clopidogrel</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010975">Platelet Aggregation Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001241" MajorTopicYN="Y">Aspirin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077144" MajorTopicYN="Y">Clopidogrel</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010975" MajorTopicYN="Y">Platelet Aggregation Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015607" MajorTopicYN="Y">Stents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003920" MajorTopicYN="Y">Diabetes Mellitus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062645" MajorTopicYN="Y">Percutaneous Coronary Intervention</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003324" MajorTopicYN="Y">Coronary Artery Disease</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000080903" MajorTopicYN="N">Dual Anti-Platelet Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055502" MajorTopicYN="N">Secondary Prevention</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">aspirin</Keyword><Keyword MajorTopicYN="N">coronary artery disease</Keyword><Keyword MajorTopicYN="N">diabetes</Keyword><Keyword MajorTopicYN="N">dual antiplatelet therapy</Keyword><Keyword MajorTopicYN="N">indobufen</Keyword><Keyword MajorTopicYN="N">percutaneous coronary intervention</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>8</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>5</Day><Hour>12</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>5</Day><Hour>6</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>5</Day><Hour>5</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>9</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40910183</ArticleId><ArticleId IdType="pmc">PMC12411781</ArticleId><ArticleId IdType="doi">10.1111/1753-0407.70152</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>GBD 2017 Causes of Death Collaborators , &#x201c;Global, Regional, and National Age&#x2010;Sex&#x2010;Specific Mortality for 282 Causes of Death in 195 Countries and Territories, 1980&#x2013;2017: A Systematic Analysis for the Global Burden of Disease Study 2017,&#x201d; Lancet 392, no. 10159 (2018): 1736&#x2013;1788.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6227606</ArticleId><ArticleId IdType="pubmed">30496103</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritsinger V., Saleh N., Lagerqvist B., and Norhammar A., &#x201c;High Event Rate After a First Percutaneous Coronary Intervention in Patients With Diabetes Mellitus: Results From the Swedish Coronary Angiography and Angioplasty Registry,&#x201d; Circulation. Cardiovascular Interventions 8, no. 6 (2015): e002328.</Citation><ArticleIdList><ArticleId IdType="pubmed">26025219</ArticleId></ArticleIdList></Reference><Reference><Citation>Grant P. J., &#x201c;Diabetes Mellitus as a Prothrombotic Condition,&#x201d; Journal of Internal Medicine 262, no. 2 (2007): 157&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">17645584</ArticleId></ArticleIdList></Reference><Reference><Citation>Undas A., Wiek I., Stepien E., Zmudka K., and Tracz W., &#x201c;Hyperglycemia Is Associated With Enhanced Thrombin Formation, Platelet Activation, and Fibrin Clot Resistance to Lysis in Patients With Acute Coronary Syndrome,&#x201d; Diabetes Care 31, no. 8 (2008): 1590&#x2013;1595.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2494657</ArticleId><ArticleId IdType="pubmed">18487475</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Weber N. C., Cohn D. M., et&#xa0;al., &#x201c;Effects of Hyperglycemia and Diabetes Mellitus on Coagulation and Hemostasis,&#x201d; Journal of Clinical Medicine 10, no. 11 (2021): 2419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8199251</ArticleId><ArticleId IdType="pubmed">34072487</ArticleId></ArticleIdList></Reference><Reference><Citation>ElSayed N. A., Aleppo G., Aroda V. R., et&#xa0;al., &#x201c;10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes&#x2010;2023,&#x201d; Diabetes Care 46, no. S1 (2023): S158&#x2013;S190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9810475</ArticleId><ArticleId IdType="pubmed">36507632</ArticleId></ArticleIdList></Reference><Reference><Citation>Angiolillo D. J., Fernandez&#x2010;Ortiz A., Bernardo E., et&#xa0;al., &#x201c;Platelet Function Profiles in Patients With Type 2 Diabetes and Coronary Artery Disease on Combined Aspirin and Clopidogrel Treatment,&#x201d; Diabetes 54, no. 8 (2005): 2430&#x2013;2435.</Citation><ArticleIdList><ArticleId IdType="pubmed">16046311</ArticleId></ArticleIdList></Reference><Reference><Citation>Angiolillo D. J. and Suryadevara S., &#x201c;Aspirin and Clopidogrel: Efficacy and Resistance in Diabetes Mellitus,&#x201d; Best Practice &amp; Research. Clinical Endocrinology &amp; Metabolism 23, no. 3 (2009): 375&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pubmed">19520310</ArticleId></ArticleIdList></Reference><Reference><Citation>Gargiulo G., Windecker S., da Costa B. R., et&#xa0;al., &#x201c;Short Term Versus Long Term Dual Antiplatelet Therapy After Implantation of Drug Eluting Stent in Patients With or Without Diabetes: Systematic Review and Meta&#x2010;Analysis of Individual Participant Data From Randomised Trials,&#x201d; BMJ 355 (2016): i5483.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5094199</ArticleId><ArticleId IdType="pubmed">27811064</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu H., Xu L., Zhao X., et&#xa0;al., &#x201c;Indobufen or Aspirin on Top of Clopidogrel After Coronary Drug&#x2010;Eluting Stent Implantation (OPTION): A Randomized, Open&#x2010;Label, End Point&#x2010;Blinded, Noninferiority Trial,&#x201d; Circulation 147, no. 3 (2023): 212&#x2013;222.</Citation><ArticleIdList><ArticleId IdType="pubmed">36335890</ArticleId></ArticleIdList></Reference><Reference><Citation>ElSayed N. A., Aleppo G., Aroda V. R., et&#xa0;al., &#x201c;2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes&#x2010;2023,&#x201d; Diabetes Care 46, no. S1 (2023): S19&#x2013;S40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9810477</ArticleId><ArticleId IdType="pubmed">36507649</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Liu J., Du Y., Lei D., and Liu H., &#x201c;Long&#x2010;Term Clinical Outcomes of Chinese Diabetic Patients After Coronary Revascularization With Drug&#x2010;Eluting Stents: A Retrospective Comparative Cohort Study,&#x201d; Annals of Translational Medicine 10, no. 22 (2022): 1206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9761126</ArticleId><ArticleId IdType="pubmed">36544638</ArticleId></ArticleIdList></Reference><Reference><Citation>Koskinas K. C., Siontis G. C., Piccolo R., et&#xa0;al., &#x201c;Impact of Diabetic Status on Outcomes After Revascularization With Drug&#x2010;Eluting Stents in Relation to Coronary Artery Disease Complexity: Patient&#x2010;Level Pooled Analysis of 6081 Patients,&#x201d; Circulation. Cardiovascular Interventions 9, no. 2 (2016): e003255.</Citation><ArticleIdList><ArticleId IdType="pubmed">26823484</ArticleId></ArticleIdList></Reference><Reference><Citation>Urban P., Mehran R., Colleran R., et&#xa0;al., &#x201c;Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention: A Consensus Document From the Academic Research Consortium for High Bleeding Risk,&#x201d; European Heart Journal 40, no. 31 (2019): 2632&#x2013;2653.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6736433</ArticleId><ArticleId IdType="pubmed">31116395</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemesle G., Meurice T., Tricot O., Lamblin N., and Bauters C., &#x201c;Association of Diabetic Status and Glycemic Control With Ischemic and Bleeding Outcomes in Patients With Stable Coronary Artery Disease: The 5&#x2010;Year CORONOR Registry,&#x201d; Journal of the American Heart Association 7, no. 10 (2018): e008354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6015307</ArticleId><ArticleId IdType="pubmed">29728374</ArticleId></ArticleIdList></Reference><Reference><Citation>De Berardis G., Lucisano G., D'Ettorre A., et&#xa0;al., &#x201c;Association of Aspirin Use With Major Bleeding in Patients With and Without Diabetes,&#x201d; JAMA 307, no. 21 (2012): 2286&#x2013;2294.</Citation><ArticleIdList><ArticleId IdType="pubmed">22706834</ArticleId></ArticleIdList></Reference><Reference><Citation>Chichareon P., Modolo R., Kogame N., et&#xa0;al., &#x201c;Association of Diabetes With Outcomes in Patients Undergoing Contemporary Percutaneous Coronary Intervention: Pre&#x2010;Specified Subgroup Analysis From the Randomized GLOBAL LEADERS Study,&#x201d; Atherosclerosis 295 (2020): 45&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">32006758</ArticleId></ArticleIdList></Reference><Reference><Citation>Ploumen E. H., Pinxterhuis T. H., Zocca P., et&#xa0;al., &#x201c;Impact of Prediabetes and Diabetes on 3&#x2010;Year Outcome of Patients Treated With New&#x2010;Generation Drug&#x2010;Eluting Stents in Two Large&#x2010;Scale Randomized Clinical Trials,&#x201d; Cardiovascular Diabetology 20, no. 1 (2021): 217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8557556</ArticleId><ArticleId IdType="pubmed">34717627</ArticleId></ArticleIdList></Reference><Reference><Citation>Meigs J. B., Mittleman M. A., Nathan D. M., et&#xa0;al., &#x201c;Hyperinsulinemia, Hyperglycemia, and Impaired Hemostasis: The Framingham Offspring Study,&#x201d; JAMA 283, no. 2 (2000): 221&#x2013;228.</Citation><ArticleIdList><ArticleId IdType="pubmed">10634338</ArticleId></ArticleIdList></Reference><Reference><Citation>Goncalves L. H., Silva M. V., Duarte R. C., et&#xa0;al., &#x201c;Acetylsalicylic Acid Therapy: Influence of Metformin Use and Other Variables on Urinary 11&#x2010;Dehydrothromboxane B2 Levels,&#x201d; Clinica Chimica Acta 429 (2014): 76&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">24316050</ArticleId></ArticleIdList></Reference><Reference><Citation>Cangemi R., Pignatelli P., Carnevale R., et&#xa0;al., &#x201c;Platelet Isoprostane Overproduction in Diabetic Patients Treated With Aspirin,&#x201d; Diabetes 61, no. 6 (2012): 1626&#x2013;1632.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3357260</ArticleId><ArticleId IdType="pubmed">22427378</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen K. H., Grove E. L., Wurtz M., Kristensen S. D., and Hvas A. M., &#x201c;Reduced Antiplatelet Effect of Aspirin During 24 Hours in Patients With Coronary Artery Disease and Type 2 Diabetes,&#x201d; Platelets 26, no. 3 (2015): 230&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pubmed">24750015</ArticleId></ArticleIdList></Reference><Reference><Citation>Tschoepe D., Roesen P., Esser J., et&#xa0;al., &#x201c;Large Platelets Circulate in an Activated State in Diabetes Mellitus,&#x201d; Seminars in Thrombosis and Hemostasis 17, no. 4 (1991): 433&#x2013;438.</Citation><ArticleIdList><ArticleId IdType="pubmed">1803514</ArticleId></ArticleIdList></Reference><Reference><Citation>Finamore F., Reny J. L., Malacarne S., Fontana P., and Sanchez J. C., &#x201c;A High Glucose Level Is Associated With Decreased Aspirin&#x2010;Mediated Acetylation of Platelet Cyclooxygenase (COX)&#x2010;1 at Serine 529: A Pilot Study,&#x201d; Journal of Proteomics 192 (2019): 258&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pubmed">30240925</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhee T. M., Bae J. W., Park K. W., et&#xa0;al., &#x201c;Aspirin vs Clopidogrel for Long&#x2010;Term Maintenance After Coronary Stenting in Patients With Diabetes: A Post Hoc Analysis of the HOST&#x2010;EXAM Trial,&#x201d; JAMA Cardiology 8, no. 6 (2023): 535&#x2013;544.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10099092</ArticleId><ArticleId IdType="pubmed">37043192</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto K., Watanabe H., Morimoto T., et&#xa0;al., &#x201c;Clopidogrel Monotherapy After 1&#x2010;Month Dual Antiplatelet Therapy in Patients With Diabetes Undergoing Percutaneous Coronary Intervention,&#x201d; JACC. Cardiovascular Interventions 16, no. 1 (2023): 19&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">36599584</ArticleId></ArticleIdList></Reference><Reference><Citation>Angiolillo D. J., Baber U., Sartori S., et&#xa0;al., &#x201c;Ticagrelor With or Without Aspirin in High&#x2010;Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention,&#x201d; Journal of the American College of Cardiology 75, no. 19 (2020): 2403&#x2013;2413.</Citation><ArticleIdList><ArticleId IdType="pubmed">32240760</ArticleId></ArticleIdList></Reference><Reference><Citation>Cattaneo M., Bevilacqua C., Lecchi A., and Mannucci P. M., &#x201c;In Vitro and Ex&#xa0;Vivo Effects of Indobufen on Human Platelet Aggregation, the Release Reaction and Thromboxane B2 Production,&#x201d; Haemostasis 17, no. 5 (1987): 293&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pubmed">3666587</ArticleId></ArticleIdList></Reference><Reference><Citation>Burch J. W., Stanford N., and Majerus P. W., &#x201c;Inhibition of Platelet Prostaglandin Synthetase by Oral Aspirin,&#x201d; Journal of Clinical Investigation 61, no. 2 (1978): 314&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC372541</ArticleId><ArticleId IdType="pubmed">413839</ArticleId></ArticleIdList></Reference><Reference><Citation>Mannucci L., Maderna P., Colli S., Lavezzari M., Sirtori C. R., and Tremoli E., &#x201c;Indobufen Is a Potent Inhibitor of Whole Blood Aggregation in Patients With a High Atherosclerotic Risk,&#x201d; Thrombosis Research 48, no. 4 (1987): 417&#x2013;426.</Citation><ArticleIdList><ArticleId IdType="pubmed">3445229</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinazzer H. and Fuccella L. M., &#x201c;Clinical Pharmacology Studies With Indobufen (K 3920): Inhibitor of Platelet Aggregation,&#x201d; Journal of Clinical Pharmacology 20, no. 5&#x2013;6 Pt 1 (1980): 316&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pubmed">7400367</ArticleId></ArticleIdList></Reference><Reference><Citation>Neergaard&#x2010;Petersen S., Hvas A. M., Grove E. L., Larsen S. B., Gregersen S., and Kristensen S. D., &#x201c;The Influence of Haemoglobin A1c Levels on Platelet Aggregation and Platelet Turnover in Patients With Coronary Artery Disease Treated With Aspirin,&#x201d; PLoS One 10, no. 7 (2015): e0132629.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4493028</ArticleId><ArticleId IdType="pubmed">26148094</ArticleId></ArticleIdList></Reference><Reference><Citation>Singla A., Antonino M. J., Bliden K. P., Tantry U. S., and Gurbel P. A., &#x201c;The Relation Between Platelet Reactivity and Glycemic Control in Diabetic Patients With Cardiovascular Disease on Maintenance Aspirin and Clopidogrel Therapy,&#x201d; American Heart Journal 158, no. 5 (2009): 784.e781&#x2013;784.e786.</Citation><ArticleIdList><ArticleId IdType="pubmed">19853698</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoos M. M., Dangas G. D., Mehran R., et&#xa0;al., &#x201c;Impact of Hemoglobin A1c Levels on Residual Platelet Reactivity and Outcomes After Insertion of Coronary Drug&#x2010;Eluting Stents (From the ADAPT&#x2010;DES Study),&#x201d; American Journal of Cardiology 117, no. 2 (2016): 192&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pubmed">26639039</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohlmorgen C., Gerfer S., Feldmann K., et&#xa0;al., &#x201c;Dapagliflozin Reduces Thrombin Generation and Platelet Activation: Implications for Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus,&#x201d; Diabetologia 64, no. 8 (2021): 1834&#x2013;1849.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8245397</ArticleId><ArticleId IdType="pubmed">34131781</ArticleId></ArticleIdList></Reference><Reference><Citation>Atherosclerosis and Coronary Heart Disease Working Group of Chinese Society of Cardiology , Interventional Cardiology Working Group of Chinese Society of Cardiology , Specialty Committee on Prevention and Treatment of Thrombosis of Chinese College of Cardiovascular Physicians , Specialty Committee on Coronary Artery Disease and Atherosclerosis of Chinese College of Cardiovascular Physicians , and Editorial Board of Chinese Journal of Cardiology , &#x201c;Chinese Society of Cardiology and Chinese College of Cardiovascular Physicians Expert Consensus Statement on Dual Antiplatelet Therapy in Patients With Coronary Artery Disease,&#x201d; Zhonghua Xin Xue Guan Bing Za Zhi 49, no. 5 (2021): 432&#x2013;454, Chinese.</Citation><ArticleIdList><ArticleId IdType="pubmed">34034377</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>